• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery.对于接受新辅助治疗和手术后的食管癌或胃食管交界癌患者,腹腔干附近的淋巴结转移应与其他淋巴结转移分开考虑。
J Thorac Dis. 2018 Mar;10(3):1511-1521. doi: 10.21037/jtd.2018.02.81.
2
Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction.远端食管或胃食管结合部腺癌患者淋巴结转移部位的预后意义。
Ann Surg. 2016 Nov;264(5):847-853. doi: 10.1097/SLA.0000000000001767.
3
The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic.胃食管交界部或食管远端癌阳性淋巴结患者中腹腔干淋巴结转移的病理意义:Mayo 诊所的外科系列研究。
Dis Esophagus. 2010 Apr;23(3):232-9. doi: 10.1111/j.1442-2050.2009.00990.x. Epub 2009 Jun 9.
4
Clinical outcomes and benefits for staging of surgical lymph node mapping after esophagectomy.食管癌切除术后手术淋巴结图谱分期的临床结果与益处
Dis Esophagus. 2017 Dec 1;30(12):1-7. doi: 10.1093/dote/dox086.
5
Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.新辅助放化疗后行食管切除术治疗初治可切除的伴有多发淋巴结转移的食管鳞状细胞癌。
Dis Esophagus. 2005;18(6):388-97. doi: 10.1111/j.1442-2050.2005.00521.x.
6
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.局部晚期食管癌的淋巴结转移:新辅助治疗如何改变其频率和分布。
Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.
7
DOES NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL AND GASTROESOPHAGEAL JUNCTION CANCER PATIENTS AFFECT POSTOPERATIVE OUTCOMES? A STUDY USING THE BECKER TUMOR REGRESSION GRADE SYSTEM AND LYMPH NODE REGRESSION.新辅助放化疗对食管胃交界部癌患者的术后结局是否有影响?使用贝克尔肿瘤退缩分级系统和淋巴结退缩评估的研究
Arq Bras Cir Dig. 2023 May 5;36:e1724. doi: 10.1590/0102-672020230002e1724. eCollection 2023.
8
Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study.食管癌淋巴结转移分布 [TIGER 研究]:一项多中心观察性研究方案。
BMC Cancer. 2019 Jul 4;19(1):662. doi: 10.1186/s12885-019-5761-7.
9
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.优化新辅助治疗食管腺癌的病理评估。
World J Gastroenterol. 2013 Dec 28;19(48):9282-93. doi: 10.3748/wjg.v19.i48.9282.
10
Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.可切除食管鳞状细胞癌新辅助化疗失败
Dis Esophagus. 2017 Sep 1;30(9):1-8. doi: 10.1093/dote/dox075.

引用本文的文献

1
Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis.病理分期和淋巴结受累情况是否会影响食管胃交界腺癌采用CROSS方案治疗后的长期肿瘤学结局?一项多中心回顾性分析。
Cancers (Basel). 2021 Feb 7;13(4):666. doi: 10.3390/cancers13040666.
2
Prognostic significance of middle paraesophageal lymph node metastasis in resectable esophageal squamous cell carcinoma: A STROBE-compliant retrospective study.可切除食管鳞状细胞癌中食管旁淋巴结转移的预后意义:一项符合STROBE标准的回顾性研究。
Medicine (Baltimore). 2019 Oct;98(43):e17531. doi: 10.1097/MD.0000000000017531.

本文引用的文献

1
Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer.卡铂和紫杉醇作为不可切除或转移性食管癌或胃癌的一线治疗方案。
Dis Esophagus. 2015 Nov-Dec;28(8):782-7. doi: 10.1111/dote.12279. Epub 2014 Aug 25.
2
Minimally invasive surgery for oesophageal cancer.食管癌的微创外科治疗。
Best Pract Res Clin Gastroenterol. 2014 Feb;28(1):41-52. doi: 10.1016/j.bpg.2013.11.002. Epub 2013 Dec 1.
3
Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia.食管胃交界区化生与食管和贲门腺癌的淋巴结转移有关。
Ann Thorac Surg. 2013 Apr;95(4):1147-53. doi: 10.1016/j.athoracsur.2012.12.040. Epub 2013 Feb 21.
4
Oesophageal carcinoma.食管癌。
Lancet. 2013 Feb 2;381(9864):400-12. doi: 10.1016/S0140-6736(12)60643-6.
5
Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction.胃食管结合部腺癌患者的肿瘤位置和站特异性淋巴结状态的术前评估。
World J Surg. 2013 Jan;37(1):147-55. doi: 10.1007/s00268-012-1804-9.
6
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
7
Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.微创与开放手术治疗食管癌的疗效比较:一项多中心、开放标签、随机对照临床试验。
Lancet. 2012 May 19;379(9829):1887-92. doi: 10.1016/S0140-6736(12)60516-9. Epub 2012 May 1.
8
Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era.现代时代食管癌确定性放化疗后腹腔干节点失败模式。
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e231-9. doi: 10.1016/j.ijrobp.2011.12.061. Epub 2012 Mar 19.
9
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.可切除食管癌新辅助化疗或放化疗后的生存:更新的荟萃分析。
Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.
10
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.局部晚期食管癌的淋巴结转移:新辅助治疗如何改变其频率和分布。
Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.

对于接受新辅助治疗和手术后的食管癌或胃食管交界癌患者,腹腔干附近的淋巴结转移应与其他淋巴结转移分开考虑。

Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery.

作者信息

Lagarde Sjoerd M, Anderegg Martinus C J, Gisbertz Suzanne S, Meijer Sybren L, Hulshof Maarten C C M, Bergman Jacques J G H M, van Laarhoven Hanneke W M, van Berge Henegouwen Mark I

机构信息

Department of Surgery, Academic Medical Center, Amsterdam, the Netherlands.

Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands.

出版信息

J Thorac Dis. 2018 Mar;10(3):1511-1521. doi: 10.21037/jtd.2018.02.81.

DOI:10.21037/jtd.2018.02.81
PMID:29707301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5906332/
Abstract

BACKGROUND

The aim of the present study is to identify the incidence and prognostic significance of lymph node metastases near the celiac trunk in patients who underwent neoadjuvant chemo(radio)therapy followed by esophagectomy.

METHODS

Between March 1994 and September 2013 a total of 462 consecutive patients with cancer of the esophagus or gastroesophageal junction (GEJ) who underwent potentially curative esophageal resection after neoadjuvant chemotherapy (N=88; 19.0%) or neoadjuvant chemoradiotherapy (CRT) (N=374; 81.0%) were included.

RESULTS

Seventy one (15.4%) patients had truncal node metastases in the resection specimen. Metastases to these nodes occurred more frequently in male patients with adenocarcinoma and in tumors at the gastro-esophageal junction. A lower response to neoadjuvant treatment, higher ypT and ypN stages and a poorer grade of differentiation were significantly related with truncal node metastases. Patients with tumor positive truncal nodes had a worse median overall survival (17 55 months). In multivariate analysis, truncal node metastases were independently associated with a worse survival. Only 22 (31.0%) of the 71 patients with tumor positive truncal nodes were identified preoperatively with EUS or CT. In contrast, 37 patients had suspicious truncal nodes on EUS or CT, but metastases in the pathology specimen were absent.

CONCLUSIONS

In the present study, it is demonstrated that positive truncal nodes in the resection specimen after neoadjuvant therapy, are associated with advanced tumor stages and are an independent factor for inferior survival.

摘要

背景

本研究的目的是确定接受新辅助化疗(放疗)后行食管切除术的患者腹腔干周围淋巴结转移的发生率及预后意义。

方法

纳入1994年3月至2013年9月期间连续462例接受新辅助化疗(n = 88;19.0%)或新辅助放化疗(CRT)(n = 374;81.0%)后行根治性食管切除术的食管癌或胃食管交界(GEJ)癌患者。

结果

71例(15.4%)患者切除标本中存在腹腔干周围淋巴结转移。这些淋巴结转移在腺癌男性患者及胃食管交界部肿瘤中更常见。新辅助治疗反应较低、ypT和ypN分期较高以及分化程度较差与腹腔干周围淋巴结转移显著相关。腹腔干周围淋巴结阳性的患者中位总生存期较差(17.55个月)。多因素分析显示,腹腔干周围淋巴结转移与较差的生存率独立相关。71例腹腔干周围淋巴结阳性患者中,术前仅22例(31.0%)通过超声内镜(EUS)或CT检查发现。相反,37例患者EUS或CT检查显示腹腔干周围淋巴结可疑,但病理标本中无转移。

结论

本研究表明,新辅助治疗后切除标本中腹腔干周围淋巴结阳性与肿瘤晚期相关,是生存较差的独立因素。